Table 1

Empagliflozin versus control group: longitudinal, full liver fat mapping by MRI-PDFF

Control group (n = 20)Empagliflozin group (n = 22)Difference between groups
Liver segmentBaselinePosttreatmentP valueBaselinePosttreatmentP valueP value
I16.3 (6.6)15.1 (6.8)0.25416.3 (6.5)11.5 (6.5)<0.00010.013
II16.1 (7.5)15.4 (6.5)0.57315.6 (7.3)11.2 (6.1)<0.00010.032
III16.6 (8.1)15.7 (7.0)0.31116.3 (6.8)11.1 (5.2)<0.00010.007
IV(A)16.7 (8.5)15.9 (6.8)0.39916.0 (7.9)11.1 (5.4)<0.00010.009
IV(B)16.0 (8.3)14.7 (7.2)0.19016.2 (7.0)11.5 (5.7)0.0010.041
V16.7 (7.5)16.2 (7.2)0.69316.6 (6.9)11.4 (4.9)<0.00010.004
VI16.5 (7.1)15.5 (7.0)0.20015.8 (6.8)11.4 (4.6)0.0010.020
VII15.8 (6.4)15.5 (6.5)0.71116.1 (7.3)10.9 (5.1)<0.00010.002
VIII16.8 (7.1)15.3 (6.8)0.05516.9 (8.0)11.3 (5.0)<0.00010.010
MRI-PDFF, average (%)16.4 (7.3)15.5 (6.7)0.05416.2 (7.0)11.3 (5.3)<0.0001<0.0001
  • Data are mean (SD) unless otherwise indicated. MRI-PDFFs measured in all nine liver segments were used to calculate segmental and overall fat fraction averages at baseline and posttreatment between the empagliflozin and control groups.